Asparkam - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Asparta is a source of potassium and magnesium ions, regulates metabolic processes. The mechanism of action is supposedly associated with the role of potassium and magnesium aspartate as a carrier of magnesium and potassium ions into the intracellular space and its participation in metabolic processes. Thus, Asparkam eliminates the imbalance of electrolytes, reduces the excitability and conductance of the myocardium (moderate antiarrhythmic effect).

Pharmacokinetics: Easily absorbed when taken orally and relatively quickly is excreted by the kidneys.

Indications:

Replenishment of the K deficit⁺ and Mg²⁺ (as part of complex therapy), incl. with ischemic heart disease (including acute myocardial infarction), chronic heart failure, arrhythmia (including against the background of an overdose of cardiac glycosides).

Contraindications:

Hypersensitivity to the drug, a violation of the exchange of amino acids, arterial hypotension, acute and chronic renal failure, hyperkalemia, hypermagnesia, violation of atrioventricular conduction (AV blockade I-III st.), oliguria, anuria, severe myasthenia gravis, acute metabolic acidosis, impaired metabolism of amino acids, dehydration (exicosis), hemolysis, Addison's disease.

Carefully:Hypophosphatemia, urolithic diathesis (associated with impaired metabolism of Ca²⁺, Mg²⁺ and ammonium phosphate), pregnancy (especially I trimester), and lactation.

Pregnancy and lactation:Carefully.

Dosing and Administration:

Aspartame is prescribed inside, after eating. Prescribe usually adults 1-2 tablets 3 times a day. The course of treatment is 3-4 weeks. If necessary, repeat the course.

Side effects:

There may be nausea, vomiting, diarrhea,pain in the epigastric region (in patients with an anatomic gastritis or cholecystitis), hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnia (hyperemia of the face, thirst, bradycardia, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions).

Overdose:

Symptoms: hyperkalemia and hypermagnia.

Treatment: intravenously calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

Interaction:

Pharmacodynamic: combined use with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, ACE inhibitors, nonsteroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and, asystole. The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter. Under the influence of potassium, undesirable effects of cardiac glycosides decrease. Magnesium reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. Anesthetics increase the oppressive effect of magnesium preparations on the central nervous system; when used simultaneously withatrakuronium, decamethonium, succinyl chloride, and suxamethonium, neuromuscular blockade may be enhanced; calcitriol increases the content of magnesium in blood plasma, calcium preparations reduce the effect of magnesium preparations.

Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs.

Pharmacokinetic: astringents and enveloping agents reduce the absorption of the drug in the gastrointestinal tract.

Special instructions:

Regular monitoring of electrolyte homeostasis is necessary.

Form release / dosage:

Pills.

Packaging:

10 tablets per contour cell pack.

1, 2, 3, 4, 5 or 6 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

For hospitals: 700 contour mesh packages with the appropriate number of instructions for use are placed in a cardboard box.

In the case of manufacturing the drug on the production site of LLC "Ozon", Russia, 10 tablets per contour cell pack.

For 10, 20, 30, 40, 50 or 100 tablets in cans of polyethylene terephthalate or cans of polymeric for medicines.

One jar or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 contour mesh packages together with the instruction for use are placed in a cardboard package.

Storage conditions:

In a dry place at a temperature of 12-25 ° C, inaccessible to children.

Shelf life:

3 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-008835/08

Date of registration:06.11.2008 / 29.12.2016

Expiration Date:Unlimited

The owner of the registration certificate:FARMAPOL-VOLGA, LLC FARMAPOL-VOLGA, LLC Russia

Manufacturer: & nbsp

FARMAPOL-VOLGA, LLC Russia

OZONE, LLC Russia

Information update date: & nbsp27.09.2017

Illustrated instructions

Instructions

Aspark (Asparcam)